Shannon Inglet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shannon Inglet has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Allison M. Butler
Statistical Data Center, Intermountain Medical Center, Murray, UT 84107, USA
1 shared publicationAmie H. Quinones
Department of Pharmacy, Intermountain Medical Center
1 shared publicationAmie Quinones
Department of Pharmacy, Intermountain Medical Center, Murray, UT 84107, USA; Department of Pharmacy, Layton Hospital, Layton, UT 84041, USA
1 shared publicationAnh Lian
Intermountain Healthcare, Taylorsville, UT, USA
1 shared publicationBradly Winter
Intermountain Healthcare, Taylorsville, UT, USA
1 shared publicationCarolyn Anctil
Utah Emergency Physicians, Murray, UT 84107, USA
1 shared publication
Latest Publications
- 2 May 2022
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 56 (12) , 1376-1381
Two Years of the COVID-19 Pandemic: What Lessons Have We Learned?
Two years ago, the World Health Organization declared a global pandemic after an outbreak of a novel coronavirus. Since then, unprecedented challenges have shaped a “new normal.” As of early March 2022, more than 6 million lives have been lost globally to COVID-19. But we have learned much over the past 2 years. Some lessons have been heartening, inspiring innovation, and adaptability; others have been devastating and will have reverberating consequences for years to come. The COVID-19 pandemic has taught us lessons that span medical, economic, social, and environmental arenas. And we still have much to learn.
- 2 May 2022
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 56 (12) , 1376-1381
Two Years of the COVID-19 Pandemic: What Lessons Have We Learned?
Two years ago, the World Health Organization declared a global pandemic after an outbreak of a novel coronavirus. Since then, unprecedented challenges have shaped a “new normal.” As of early March 2022, more than 6 million lives have been lost globally to COVID-19. But we have learned much over the past 2 years. Some lessons have been heartening, inspiring innovation, and adaptability; others have been devastating and will have reverberating consequences for years to come. The COVID-19 pandemic has taught us lessons that span medical, economic, social, and environmental arenas. And we still have much to learn.
- 1 August 2020
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 38 (8) , 1568-1571
Patient utilization of prescription opioids after discharge from the emergency department
- 1 August 2020
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 38 (8) , 1568-1571
Patient utilization of prescription opioids after discharge from the emergency department
- 2 June 2020
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 54 (11) , 1109-1143
Clinical Data for the Use of Cannabis-Based Treatments: A Comprehensive Review of the Literature
Objective: To compile and synthesize the available literature describing medical cannabis use across various disease states. Data Sources: PubMed, EBSCO, and Google Scholar searches were conducted using MeSH and/or keywords. Study Selection and Data Extraction: Studies were included if they described the use of cannabis-based products and medications in the treatment of a predefined list of disease states in humans and were published in English. The extraction period had no historical limit and spanned through April 2019. Data Synthesis: Evidence was compiled and summarized for the following medical conditions: Alzheimer disease, amyotrophic lateral sclerosis, autism, cancer and cancer-associated adverse effects, seizure disorders, human immunodeficiency virus, inflammatory bowel disease, multiple sclerosis (MS), nausea, pain, posttraumatic stress disorder, and hospice care. Relevance to Patient Care and Clinical Practice: Based on identified data, the most robust evidence suggests that medical cannabis may be effective in the treatment of chemotherapy-induced nausea and vomiting, seizure disorders, MS-related spasticity, and pain (excluding diabetic neuropathy). Overall, the evidence is inconsistent and generally limited by poor quality. The large variation in cannabis-based products evaluated in studies limits the ability to make direct comparisons. Regardless of the product, a gradual dose titration was utilized in most studies. Cannabis-based therapies were typically well tolerated, with the most common adverse effects being dizziness, somnolence, dry mouth, nausea, and euphoria. Conclusions: As more states authorize medical cannabis use, there is an increasing need for high-quality clinical evidence describing its efficacy and safety. This review is intended to serve as a reference for clinicians, so that the risks and realistic benefits of medical cannabis are better understood.
- 2 June 2020
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 54 (11) , 1109-1143
Clinical Data for the Use of Cannabis-Based Treatments: A Comprehensive Review of the Literature
Objective: To compile and synthesize the available literature describing medical cannabis use across various disease states. Data Sources: PubMed, EBSCO, and Google Scholar searches were conducted using MeSH and/or keywords. Study Selection and Data Extraction: Studies were included if they described the use of cannabis-based products and medications in the treatment of a predefined list of disease states in humans and were published in English. The extraction period had no historical limit and spanned through April 2019. Data Synthesis: Evidence was compiled and summarized for the following medical conditions: Alzheimer disease, amyotrophic lateral sclerosis, autism, cancer and cancer-associated adverse effects, seizure disorders, human immunodeficiency virus, inflammatory bowel disease, multiple sclerosis (MS), nausea, pain, posttraumatic stress disorder, and hospice care. Relevance to Patient Care and Clinical Practice: Based on identified data, the most robust evidence suggests that medical cannabis may be effective in the treatment of chemotherapy-induced nausea and vomiting, seizure disorders, MS-related spasticity, and pain (excluding diabetic neuropathy). Overall, the evidence is inconsistent and generally limited by poor quality. The large variation in cannabis-based products evaluated in studies limits the ability to make direct comparisons. Regardless of the product, a gradual dose titration was utilized in most studies. Cannabis-based therapies were typically well tolerated, with the most common adverse effects being dizziness, somnolence, dry mouth, nausea, and euphoria. Conclusions: As more states authorize medical cannabis use, there is an increasing need for high-quality clinical evidence describing its efficacy and safety. This review is intended to serve as a reference for clinicians, so that the risks and realistic benefits of medical cannabis are better understood.
- Open Access
- 8 March 2018
- Published by David Publishing Company in Journal of Pharmacy and Pharmacology
- Vol. 6 (3)
Evaluation of Opioid Reversal with Naloxone before and after Implementation of a Computerized Physician Order Entry System at a Tertiary Medical Center
- 8 March 2018
- Published by David Publishing Company in Journal of Pharmacy and Pharmacology
- Vol. 6 (3)
Open AccessEvaluation of Opioid Reversal with Naloxone before and after Implementation of a Computerized Physician Order Entry System at a Tertiary Medical Center
- Open Access
- 26 August 2016
- Published by Springer Nature in Cureus
- Vol. 8 (8) , e753
Seizure Prophylaxis in Patients with Traumatic Brain Injury: A Single-Center Study
The use of prophylactic anticonvulsants to prevent early post-traumatic seizures (PTSs) is recommended but inconsistently employed in patients with traumatic brain injury (TBI). The authors evaluated outcomes associated with prophylaxis administration in patients with TBI at a Level 1 trauma center. All patients admitted with TBI from October 2007 through May 2012 were included. Our primary outcome was the incidence of early PTSs. Secondary outcomes included mortality, length of hospital and intensive care unit (ICU) stays, and incidence of late seizures. Of the 2,111 patients with TBI, 557 (26.4%) received seizure prophylaxis and 1,554 (73.6%) did not. Two early PTSs occurred in the prophylaxis group (0.4%), whereas 21 occurred in the non-prophylaxis group (1.4%) (p = 0.05). The overall mortality rate was higher in patients who received prophylaxis (14.2% vs. 6.2%; p < 0.001), and the mean hospital length of stay (LOS) was longer (6.8 ± 6.9 vs. 3.8 ± 5 days; p < 0.001). In patients with severe and moderate TBI, the rate of prophylaxis administration was approximately half, whereas significantly fewer patients with mild TBI received prophylaxis than did not (20.2% vs 79.8%, p < 0.001). Lower Glasgow Coma Scale (GCS) score and longer hospital LOS were associated with early PTS (p = 0.008 for both comparisons), but sex and age were not. Brain hemorrhage was present in 78.3% of those patients who experienced early seizures. In our cohort, patients who received seizure prophylaxis had a lower GCS score, higher overall mortality rate, longer LOS, and more frequent ICU admissions, suggesting that patients who received prophylaxis were likely more severely injured.
- 26 August 2016
- Published by Springer Nature in Cureus
- Vol. 8 (8) , e753
Open AccessSeizure Prophylaxis in Patients with Traumatic Brain Injury: A Single-Center Study
The use of prophylactic anticonvulsants to prevent early post-traumatic seizures (PTSs) is recommended but inconsistently employed in patients with traumatic brain injury (TBI). The authors evaluated outcomes associated with prophylaxis administration in patients with TBI at a Level 1 trauma center. All patients admitted with TBI from October 2007 through May 2012 were included. Our primary outcome was the incidence of early PTSs. Secondary outcomes included mortality, length of hospital and intensive care unit (ICU) stays, and incidence of late seizures. Of the 2,111 patients with TBI, 557 (26.4%) received seizure prophylaxis and 1,554 (73.6%) did not. Two early PTSs occurred in the prophylaxis group (0.4%), whereas 21 occurred in the non-prophylaxis group (1.4%) (p = 0.05). The overall mortality rate was higher in patients who received prophylaxis (14.2% vs. 6.2%; p < 0.001), and the mean hospital length of stay (LOS) was longer (6.8 ± 6.9 vs. 3.8 ± 5 days; p < 0.001). In patients with severe and moderate TBI, the rate of prophylaxis administration was approximately half, whereas significantly fewer patients with mild TBI received prophylaxis than did not (20.2% vs 79.8%, p < 0.001). Lower Glasgow Coma Scale (GCS) score and longer hospital LOS were associated with early PTS (p = 0.008 for both comparisons), but sex and age were not. Brain hemorrhage was present in 78.3% of those patients who experienced early seizures. In our cohort, patients who received seizure prophylaxis had a lower GCS score, higher overall mortality rate, longer LOS, and more frequent ICU admissions, suggesting that patients who received prophylaxis were likely more severely injured.